In January 2020, Stephen Hahn, M.D., had been running the FDA for just a few weeks when the COVID-19 virus sequence was published. Despite the odds, in just eleven months, the first mRNA vaccine was authorized. It was the fastest development of its kind in history. And the part Hahn can't stop thinking about isn't how hard it was. It's what it proved: medicine can move that fast, even though it usually doesn't.

Now, as Chief Executive Officer of Nucleus RadioPharma, he makes a new argument for data science leaders: the hard part in medicine isn’t the science. It’s what we do with the data.

Stephen brings:

• Why he calls AI in molecule discovery “table stakes”
• What leading the largest real-world experiment in history taught him
• How the FDA compressed years into months, and how we can do it again

Justin Johnson sat down one afternoon to build a new capability for ARIA, the AI research agent he runs on a supercomputer that sits on his desk. Before writing a single line, he checked what was already there and found that his own system had designed and built the exact thing he was about to start. Three months earlier. While he was asleep.

That was the moment Justin went, in his words, from first mover to second mover on his own project, and he's still working out what that means.

Justin brings:

• How the “second mover” gap is widening
• Where most senior data science leaders really fall on the copilot-versus-harness divide
• How the old trade-off between mission and frontier technology is collapsing in biopharma

Be sure to check out Justin’s book, Builder-Leader: The AI Exoskeleton That Crosses the Gap, and his blog, Run Data Run.

Dave Johnson’s first pharma job wasn't in a lab. It was in a room, dark and cramped, stacked floor to ceiling with 30 years of decaying discovery chemistry data on every storage medium imaginable.

They called it “the cave.”

A physicist turned data leader, Dave has spent two decades solving the same problem: scientific data is generated for one purpose, poorly captured, and left abandoned.

Now co-founding Dash Bio after years leading data science at Moderna, Dave joins Thomas to make a case the industry would rather not hear: AI pilots keep failing because organizations can't understand their own data or tell whether anything they build improves how they work.

Listen in to hear:

• Why "the cave" is still an accurate description of how most pharma companies manage data
• Why clinical trial numbers mean nothing without the metadata behind them
• How the US needs to treat China’s clinical trial volume as a wake-up call